Open Peer Review on Qeios

Spebrutinib

National Cancer Institute

Source

National Cancer Institute. <u>Spebrutinib</u>. NCI Thesaurus. Code C97037.

An orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, spebrutinib targets and covalently binds to BTK, thereby preventing its activity. By irreversibly inhibiting BTK, administration of this agent may lead to an inhibition of B cell receptor (BCR) signaling and may inhibit cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the T ec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.